Publications found:
36,694
Sort by:
Idiopathic CD4+ Lymphocytopenia - Pipeline Insight, 2019
US$ 1,250.00
... disease overview and Idiopathic CD4+ Lymphocytopenia treatment guidelines. The assessment part of the report embraces, in depth Idiopathic CD4+ Lymphocytopenia commercial assessment and clinical assessment of the pipeline products under ...
August 2019
60 pages
Lactose Intolerance - Pipeline Insight, 2019
US$ 1,250.00
... Lactose malassimilation. Lactose Intolerance Pipeline Development Activities The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs ... proprietary databases, company/university websites, clinical trial registries, conferences, ...
August 2019
60 pages
Lambert-Eaton Myasthenic Syndrome (LEMS)- Pipeline Insight, 2019
US$ 1,250.00
... disease overview and Lambert-Eaton Myasthenic Syndrome (LEMS) treatment guidelines. The assessment part of the report embraces, in depth Lambert-Eaton Myasthenic Syndrome (LEMS) commercial assessment and clinical assessment of the pipeline products under ...
August 2019
60 pages
Phosphoglucomutase (PGM 1) Deficiency- Pipeline Insight, 2019
US$ 1,250.00
... report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form. Phosphoglucomutase (PGM 1) Deficiency Clinical Assessment of products ...
August 2019
60 pages
Post-Transplant Lymphoproliferative Disorder- Pipeline Insight, 2019
US$ 1,250.00
... post-transplant lymphoproliferative disease. Early diagnosis and prompt treatment of these disorders are extremely important. Post-Transplant Lymphoproliferative Disorder Pipeline Development Activities The report provides insights ... databases, company/university websites, clinical trial registries, conferences ...
August 2019
60 pages
Primary Biliary Cholangitis - Pipeline Insight, 2019
US$ 1,250.00
... disease overview and Primary Biliary Cholangitis treatment guidelines. The assessment part of the report embraces, in depth Primary Biliary Cholangitis commercial assessment and clinical assessment of the pipeline products under ...
August 2019
60 pages
Primary Progressive Aphasia - Pipeline Insight, 2019
US$ 1,250.00
... disease overview and Primary Progressive Aphasia treatment guidelines. The assessment part of the report embraces, in depth Primary Progressive Aphasia commercial assessment and clinical assessment of the pipeline products under ...
August 2019
60 pages
Proteus Syndrome - Pipeline Insight, 2019
US$ 1,250.00
... Proteus syndrome. Proteus Syndrome Pipeline Development Activities The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs ... 's proprietary databases, company/university websites, clinical trial registries, conferences, SEC ...
August 2019
60 pages
Pruritis - Pipeline Insight, 2019
US$ 1,250.00
... 24 Hours "Pruritis - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present ... Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Pruritis ... databases, company/university websites, clinical trial registries, ...
August 2019
60 pages
Pseudoxanthoma Elasticum- Pipeline Insight, 2019
US$ 1,250.00
... Pseudoxanthoma Elasticum- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pseudoxanthoma Elasticum pipeline ... databases, company/university websites, clinical trial registries, conferences ...
August 2019
60 pages
Pyoderma Gangrenosum (PG) - Pipeline Insight, 2019
US$ 1,250.00
... Pyoderma Gangrenosum treatment guidelines. The assessment part of the report embraces, in depth Pyoderma Gangrenosum commercial assessment and clinical assessment of the pipeline ... from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, ...
August 2019
60 pages
Recessive Dystrophic Epidermolysis (RDEB)- Pipeline Insight, 2019
US$ 1,250.00
... RDEB-SG. Recessive Dystrophic Epidermolysis Pipeline Development Activities The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs ... 's proprietary databases, company/university websites, clinical trial registries, conferences, ...
August 2019
60 pages
Refractory Epilepsy- Pipeline Insight, 2019
US$ 1,250.00
... Refractory Epilepsy- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Epilepsy pipeline ... proprietary databases, company/university websites, clinical trial registries, conferences, ...
August 2019
60 pages
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019
US$ 3,500.00
... P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
61 pages
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019
US$ 3,500.00
... P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
50 pages
72 kDa Type IV Collagenase - Pipeline Review, H2 2019
US$ 3,500.00
... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) development landscape Develop ...
August 2019
32 pages
Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019
US$ 3,500.00
... Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
88 pages
Bcl 2 Like Protein 1 - Pipeline Review, H2 2019
US$ 3,500.00
... Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
59 pages
Cathepsin K - Pipeline Review, H2 2019
US$ 3,500.00
... reviews Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
40 pages
Integrin Alpha 4 - Pipeline Review, H2 2019
US$ 3,500.00
... Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
87 pages
Integrin Beta 7 - Pipeline Review, H2 2019
US$ 3,500.00
... Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
54 pages
Intercellular Adhesion Molecule 1 - Pipeline Review, H2 2019
US$ 3,500.00
... Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
47 pages
Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019
US$ 3,500.00
... Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
44 pages
Mucin 1 - Pipeline Review, H2 2019
US$ 3,500.00
... reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development ...
August 2019
92 pages
Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019
US$ 3,500.00
... being developed by Companies/Universities. It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with ...
August 2019
119 pages
Peroxisome Proliferator Activated Receptor Delta - Pipeline Review, H2 2019
US$ 3,500.00
... also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics development with respective active and dormant ...
August 2019
106 pages
Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019
US$ 3,500.00
... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape Develop and ...
August 2019
99 pages
Alexion Pharmaceuticals Performance, Capabilities, Goals and Strategies
US$ 850.00
... and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Direction. ... current suppliers realistically assess their financial, technological and marketing capabilities vis-à-vis its competitors. To assist potential market entrants ...
August 2019
-
Alnylam Pharmaceuticals Performance, Capabilities, Goals and Strategies
US$ 850.00
... and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Direction. ... current suppliers realistically assess their financial, technological and marketing capabilities vis-à-vis its competitors. To assist potential market entrants ...
August 2019
-
Amgen Performance, Capabilities, Goals and Strategies
US$ 850.00
... and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Direction. ... current suppliers realistically assess their financial, technological and marketing capabilities vis-à-vis its competitors. To assist potential market entrants ...
August 2019
-
Biogen Performance, Capabilities, Goals and Strategies
US$ 850.00
... and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Direction. ... current suppliers realistically assess their financial, technological and marketing capabilities vis-à-vis its competitors. To assist potential market entrants ...
August 2019
-
Exelixis Performance, Capabilities, Goals and Strategies
US$ 850.00
... and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Direction. ... current suppliers realistically assess their financial, technological and marketing capabilities vis-à-vis its competitors. To assist potential market entrants ...
August 2019
-
Gilead Sciences Performance, Capabilities, Goals and Strategies
US$ 850.00
... and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Direction. ... current suppliers realistically assess their financial, technological and marketing capabilities vis-à-vis its competitors. To assist potential market entrants ...
August 2019
-
Incyte Performance, Capabilities, Goals and Strategies
US$ 850.00
... and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Direction. ... current suppliers realistically assess their financial, technological and marketing capabilities vis-à-vis its competitors. To assist potential market entrants ...
August 2019
-
Top 10 Pharmaceutical Companies Capabilities, Goals and Strategies
US$ 4,500.00
... capabilities in relation to the leading competitors. The series includes current assessments of more than 1,000 companies worldwide. Depending on the company’s ... effective marketing and R&D programs. In the dynamic and fragmented Pharmaceutical industry, besieged by intense competition and rapid change of ...
August 2019
-
